Research on Clinical Treatment of Mesothelioma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: 10 January 2025 | Viewed by 181
Special Issue Editors
2. Unit of Respiratory System Diseases, Cardio-Thoracic and Vascular Department, IRCCS Fondazione Policlinico San Matteo, 27100 Pavia, Italy
Interests: thoracic cancers; personalized medicine; oncogenomics; metastatic process
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pleural mesothelioma (PM) is a rare and aggressive neoplasm that originates from the pleural mesothelium and whose onset is mainly linked to occupational and/or environmental exposure to asbestos. Conventional chemotherapy as well as targeted therapies have failed against disease progression and patients’ prognoses are still poor; in some instances, supportive care is the only therapeutic option. However, the advent of immunotherapy, the development of advanced cell therapy platforms, and the application of innovative technologies in cancer management have allowed some effective improvement in PM as well.
Thus, the aim of the present Special Issue is to recapitulate the current standard of care for this orphan cancer and to focus on novel and more promising approaches in PM screening, diagnosis, and treatment.
Dr. Giulia M. Stella
Dr. Walid Hadid
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pleural mesothelioma
- targeted therapy
- local treatments
- radiomics
- genetic traits
- occupational health
- asbestos exposure
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
